NASDAQ:AXNX Axonics (AXNX) Stock Price, News & Analysis $68.49 +0.30 (+0.44%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$68.25▼$68.5550-Day Range$66.80▼$68.1952-Week Range$48.30▼$69.68Volume498,909 shsAverage Volume863,556 shsMarket Capitalization$3.49 billionP/E RatioN/ADividend YieldN/APrice Target$69.78 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Axonics alerts: Email Address Axonics MarketRank™ Stock AnalysisAnalyst RatingHold2.27 Rating ScoreUpside/Downside1.9% Upside$69.78 Price TargetShort InterestBearish6.35% of Shares Sold ShortDividend StrengthN/ASustainability-1.38Upright™ Environmental ScoreNews Sentiment1.41Based on 4 Articles This WeekInsider TradingN/AProj. Earnings Growth407.69%From $0.13 to $0.66 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.38 out of 5 starsMedical Sector327th out of 936 stocksSurgical & Medical Instruments Industry41st out of 101 stocks 1.1 Analyst's Opinion Consensus RatingAxonics has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on 3 buy ratings, 8 hold ratings, and no sell ratings.Amount of Analyst CoverageAxonics has only been the subject of 1 research reports in the past 90 days.Read more about Axonics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.35% of the outstanding shares of Axonics have been sold short.Short Interest Ratio / Days to CoverAxonics has a short interest ratio ("days to cover") of 8.6.Change versus previous monthShort interest in Axonics has recently decreased by 4.71%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAxonics does not currently pay a dividend.Dividend GrowthAxonics does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAxonics has received a 59.34% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Incontinence medication", "Implants and prostheses", and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Axonics is -1.38. Previous Next 4.1 News and Social Media Coverage News SentimentAxonics has a news sentiment score of 1.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Axonics this week, compared to 3 articles on an average week.Search Interest2 people have searched for AXNX on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Axonics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Axonics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.85% of the stock of Axonics is held by insiders.Percentage Held by Institutions99.48% of the stock of Axonics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Axonics' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Axonics are expected to grow by 407.69% in the coming year, from $0.13 to $0.66 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Axonics is -214.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Axonics is -214.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxonics has a P/B Ratio of 5.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Axonics Stock (NASDAQ:AXNX)Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.Read More AXNX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AXNX Stock News HeadlinesJuly 24 at 11:51 AM | americanbankingnews.comAxonics (NASDAQ:AXNX) and Orthofix Medical (NASDAQ:OFIX) Head-To-Head AnalysisMay 16, 2024 | marketwatch.comAxonics Gets Australian Approval for Neurostimulator SystemJuly 27, 2024 | Paradigm Press (Ad)Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.May 16, 2024 | businesswire.comAxonics Receives Regulatory Approval for Recharge-Free SNM System in AustraliaMay 1, 2024 | markets.businessinsider.comWhat 23 Analyst Ratings Have To Say About Eli Lilly and CoMay 1, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: 10x Genomics (TXG), Axonics Modulation Technologies (AXNX) and Eli Lilly & Co (LLY)April 30, 2024 | investorplace.comAXNX Stock Earnings: Axonics Misses EPS, Beats Revenue for Q1 2024April 30, 2024 | businesswire.comAxonics Reports First Quarter 2024 Financial ResultsJuly 27, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.April 24, 2024 | prnewswire.comBoston Scientific Announces Results for First Quarter 2024April 4, 2024 | reuters.comFTC seeks more information on Boston Scientific's $3.7 bln Axonics dealMarch 22, 2024 | businesswire.comAxonics Stockholders Approve Merger Agreement with Boston ScientificMarch 21, 2024 | businesswire.comAxonics Provides Update on Inter Partes Review ProceedingsMarch 14, 2024 | businesswire.comAxonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation SystemMarch 1, 2024 | finance.yahoo.comAxonics Full Year 2023 Earnings: EPS Beats ExpectationsFebruary 29, 2024 | marketwatch.comAxonics Pushes Back Against Patent Dispute Alleged by MedtronicFebruary 29, 2024 | businesswire.comAxonics Responds to ITC Action by MedtronicFebruary 29, 2024 | markets.businessinsider.comBeyond The Numbers: 7 Analysts Discuss Axonics StockSee More Headlines Receive AXNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Axonics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/30/2024Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:AXNX CUSIPN/A CIK1603756 Webwww.axonics.com Phone(949) 396-6322Fax949-396-6321Employees610Year FoundedN/APrice Target and Rating Average Stock Price Target$69.78 High Stock Price Target$71.00 Low Stock Price Target$63.00 Potential Upside/Downside+1.9%Consensus RatingHold Rating Score (0-4)2.27 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($0.32) Trailing P/E RatioN/A Forward P/E Ratio526.85 P/E GrowthN/ANet Income$-6,090,000.00 Net Margins-4.12% Pretax Margin-3.60% Return on Equity-2.58% Return on Assets-2.32% Debt Debt-to-Equity RatioN/A Current Ratio9.96 Quick Ratio8.04 Sales & Book Value Annual Sales$366.38 million Price / Sales9.54 Cash Flow$0.13 per share Price / Cash Flow538.45 Book Value$12.59 per share Price / Book5.44Miscellaneous Outstanding Shares51,020,000Free Float50,074,000Market Cap$3.49 billion OptionableOptionable Beta0.83 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Raymond W. Cohen (Age 65)CEO & Director Comp: $1.75MMs. Kari Keese (Age 39)Chief Financial Officer Comp: $1.64MMr. Rinda K. Sama (Age 45)Chief Operating Officer Comp: $888.2kDr. John Woock Ph.D. (Age 41)Executive VP, Chief Marketing & Strategy Officer Comp: $888.2kMr. Alfred J. Ford Jr. (Age 53)Chief Commercial Officer Comp: $909.52kMr. Guangqiang Jiang Ph.D. (Age 50)Chief Technology Officer Mr. Neil BhalodkarVice President of Investor RelationsMr. Aaron PettitGeneral Counsel & Chief Compliance OfficerMr. Michael V. Williamson Esq. (Age 52)J.D., Senior VP, General & IP Counsel Dr. Karen L. Noblett M.A.S. (Age 61)M.D., Chief Medical Officer Comp: $651.4kMore ExecutivesKey CompetitorsCantel MedicalNYSE:CMDNuVasiveNASDAQ:NUVACardiovascular SystemsNASDAQ:CSIIInovio PharmaceuticalsNASDAQ:INOInsuletNASDAQ:PODDView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 23,460 shares on 7/26/2024Ownership: 0.428%Hedges Asset Management LLCSold 300 shares on 7/19/2024Ownership: 0.006%Oak Ridge Investments LLCSold 2,837 shares on 7/17/2024Ownership: 0.188%Granite Bay Wealth Management LLCBought 25,200 shares on 7/15/2024Ownership: 0.049%QRG Capital Management Inc.Bought 2,405 shares on 7/12/2024Ownership: 0.028%View All Insider TransactionsView All Institutional Transactions AXNX Stock Analysis - Frequently Asked Questions How have AXNX shares performed this year? Axonics' stock was trading at $62.23 at the beginning of 2024. Since then, AXNX stock has increased by 10.1% and is now trading at $68.49. View the best growth stocks for 2024 here. How were Axonics' earnings last quarter? Axonics, Inc. (NASDAQ:AXNX) posted its earnings results on Tuesday, April, 30th. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by $0.32. The business's quarterly revenue was up 29.4% on a year-over-year basis. What is Raymond W. Cohen's approval rating as Axonics' CEO? 20 employees have rated Axonics Chief Executive Officer Raymond W. Cohen on Glassdoor.com. Raymond W. Cohen has an approval rating of 89% among the company's employees. 73.0% of employees surveyed would recommend working at Axonics to a friend. When did Axonics IPO? Axonics (AXNX) raised $100 million in an IPO on Wednesday, October 31st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers. Who are Axonics' major shareholders? Top institutional investors of Axonics include Bank of New York Mellon Corp (0.43%), Oak Ridge Investments LLC (0.19%), Granite Bay Wealth Management LLC (0.05%) and Summit Securities Group LLC. Insiders that own company stock include Raymond W Cohen, John Woock, Rinda Sama, Kari Leigh Keese, Alfred J Ford Jr, Karen Noblett, Danny L Dearen, Jane E Kiernan and Esteban Lopez. View institutional ownership trends. How do I buy shares of Axonics? Shares of AXNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Axonics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Axonics investors own include RTX (RTX), Oasis Petroleum (OAS), Pfizer (PFE), Procter & Gamble (PG), Thermo Fisher Scientific (TMO) and Cisco Systems (CSCO). This page (NASDAQ:AXNX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axonics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Axonics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
